Best Practice & Research Clinical Haematology
Volume 22, Issue 4 , Pages 517-521 , December 2009

Is there a role for maintenance therapy in acute myeloid leukaemia?

  • Maria R. Baer, MD (Professor of Medicine)

      Affiliations

    • Corresponding Author InformationTel.: +1 410 328 8708; Fax: +1 410 328 6896.

References 

  1. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. The New England journal of medicine. 2006;354:166–178
  2. Jabbour EJ, Faderl S, Kantarjian HM. Adult acute lymphoblastic leukemia. Mayo Clinic proceedings. 2005;80:1517–1527
  3. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009;113:1875–1891
  4. Fenaux P, Mufti GJ, Hellstrom–Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher–risk myelodysplastic syndromes: a randomised, open–label, phase III study. The lancet oncology. 2009;10:223–232
  5. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, et al. Age and acute myeloid leukemia. Blood. 2006;107:3481–3485
  6. Raza A, Maheshwari Y, Preisler HD. Differences in cell cycle characteristics among patients with acute nonlymphocytic leukemia. Blood. 1987;69:1647–1653
  7. Preisler H, Davis RB, Kirshner J, et al. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study. Blood. 1987;69:1441–1449
  8. Sauter C, Berchtold W, Fopp M, et al. Acute myelogenous leukaemia: maintenance chemotherapy after early consolidation treatment does not prolong survival. Lancet. 1984;1:379–382
  9. Lowenberg B, Suciu S, Archimbaud E, et al. Mitoxantrone versus daunorubicin in induction–consolidation chemotherapy––the value of low–dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European organization for the research and treatment of cancer and the Dutch–Belgian hemato–oncology cooperative hovon group. Journal of Clinical Oncology. 1998;16:872–881
  10. Miyawaki S, Sakamaki H, Ohtake S, et al. A randomized, postremission comparison of four courses of standard–dose consolidation therapy without maintenance therapy versus three courses of standard–dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult leukemia study group AML 97 study. Cancer. 2005;104:2726–2734
  11. Baer MR, George SL, Caligiuri MA, et al. Low–dose interleukin–2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. Journal of Clinical Oncology. 2008;26:4934–4939
  12. Kolitz JE, Hars V, DeAngelo DJ, et al. Phase III trial of immunotherapy with recombinant interleukin–2 (rIL–2) versus observation in patients < 60 years with acute myeloid leukemia (AML) in first remission (CR1): preliminary results from Cancer and Leukemia Group B (CALGB) 19808. Blood. 2007;110:53a;abstr 157
  13. Brune M, Castaigne S, Catalano J, et al. Improved leukemia–free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin–2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood. 2006;108:88–96
  14. Greiner J, Döhner H, Schmitt M. Cancer vaccines for patients with acute myeloid leukemia––definition of leukemia–associated antigens and current clinical protocols targeting these antigens. Haematologica. 2006;91:1653–1661
  15. Houtenbos I, Westers TM, Ossenkoppele GJ, van de Loosdrecht AA. Leukemia–derived dendritic cells: towards clinical vaccination protocols in acute myeloid leukemia. Haematologica. 2006;91:348–355
  16. National Cancer Institute. Phase II study of maintenance therapy with decitabine after standard induction and cytogenetic risk–adapted intensification in patients with previously untreated acute myeloid leukemia. Clinical Trials (PDQ) 5/13/2009.
  17. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome–positive acute lymphocytic leukemia with hyper–CVAD and imatinib mesylate. Blood. 2004;103:4396–4407
  18. Karp JE, Smith BD, Gojo I, et al. Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor–risk features. Clinical cancer research. 2008;14:3077–3082
  19. Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small–molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. 2005;105:54–60
  20. Piloto O, Wright M, Brown P, et al. Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. Blood. 2007;109:1643–1652

PII: S1521-6926(09)00064-4

doi: 10.1016/j.beha.2009.09.001

Best Practice & Research Clinical Haematology
Volume 22, Issue 4 , Pages 517-521 , December 2009

Article Tools